Has Naomi Watts confirmed she uses HRT?

Yes. Watts has confirmed in multiple public interviews, including with People and The New York Times, that she uses hormone replacement therapy to manage menopause symptoms. She has not disclosed the specific drug or formulation.

What is Stripes Beauty?

Stripes Beauty is a menopause-focused wellness brand Watts founded in 2022. It sells topical products and supplements. It is not a prescription HRT provider.

Is early menopause dangerous?

Early menopause (before age 45) is associated with increased risks of osteoporosis, cardiovascular disease, and cognitive decline due to prolonged estrogen deficiency. The Endocrine Society recommends HRT at least until the average age of natural menopause for women in this group.

What are the main types of HRT?

Systemic options include oral estradiol, transdermal patches, gels, and sprays. Women with a uterus also take a progestogen (commonly micronized progesterone). Low-dose vaginal estrogen is used for localized genitourinary symptoms.

Does HRT cause breast cancer?

Combined estrogen-progestogen therapy is associated with a small absolute increase in breast cancer risk after approximately five years of use. Estrogen-only therapy carries a lower or neutral risk. The type of progestogen and the duration of use both influence outcomes.

Naomi Watts and Women's HRT: The Documented Public Record

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Naomi Watts and Women's HRT: The Documented Public Record Image: HealthRX.com clinical image

What Naomi Watts Has Said Publicly About HRT and Menopause

Naomi Watts entered perimenopause in her mid-thirties, far earlier than the average onset age of 47. She has spoken about this timeline repeatedly in interviews, describing years of symptoms she did not initially understand. In a 2023 interview with People magazine, Watts disclosed that she began experiencing hot flashes, brain fog, and sleep disruption well before turning 40.

Watts has confirmed publicly that she uses hormone replacement therapy as part of her menopause management. In conversations with outlets including The New York Times and Today, she described HRT as a turning point in how she felt day to day. She has been explicit that her advocacy is rooted in personal experience: she tried to conceive while already in perimenopause and felt that medical guidance at the time was insufficient.

In 2022, Watts launched Stripes Beauty, a direct-to-consumer brand offering topical products and supplements designed for women in menopause. The brand's positioning bridges consumer beauty with menopausal health. Watts has described the company as her response to what she experienced as a clinical and cultural gap in menopause care.

At a glance

Status: Confirmed HRT user; disclosed in multiple public interviews
Onset: Perimenopause began in her mid-thirties (self-reported)
Public role: Founded Stripes Beauty (2022), a menopause-focused wellness brand
Advocacy focus: HRT access, menopause destigmatization, earlier clinical screening
Drug family: Women's hormone replacement therapy (specific formulation not publicly disclosed)

Clinical Context: What HRT Actually Does

Hormone replacement therapy for menopause replaces estrogen (and, for women with a uterus, progesterone) that the ovaries stop producing as they reach functional decline. The primary FDA-approved indications include treatment of vasomotor symptoms (hot flashes, night sweats), prevention of bone loss, and management of genitourinary syndrome of menopause.

Estrogen acts on thermoregulatory centers in the hypothalamus. When circulating estradiol drops during the menopausal transition, the thermoneutral zone narrows. Small increases in core body temperature then trigger vasodilation and sweating. Exogenous estrogen restores that thermoneutral zone and reduces vasomotor episodes by 75% or more in most women.

Standard systemic HRT options include oral estradiol (typically 0.5 to 2 mg daily), transdermal patches (delivering 0.025 to 0.1 mg per day), and topical gels or sprays. Women with an intact uterus also take a progestogen, either cyclically or continuously, to prevent endometrial hyperplasia. Micronized progesterone (100 to 200 mg oral) is the most commonly prescribed form in current practice, based on data from the KEEPS trial and E3N cohort study suggesting a more favorable breast cancer risk profile compared to synthetic progestins.

Watts has not publicly named the specific HRT formulation she uses. That is her medical information to share or withhold, and no responsible source should speculate beyond what she has confirmed.

The Timing Question: Why Early Menopause Changes the Calculus

Watts has described entering perimenopause around age 36. Premature ovarian insufficiency (menopause before 40) affects roughly 1% of women, while early menopause (before 45) affects approximately 5%. The clinical significance of early onset is substantial. Prolonged estrogen deficiency increases the lifetime risk of osteoporosis, cardiovascular disease, cognitive decline, and genitourinary atrophy.

For women who reach menopause before 45, the Endocrine Society clinical practice guidelines recommend HRT at minimum until the average age of natural menopause (approximately 51), unless a contraindication exists. The reasoning is straightforward: these women are not adding hormones beyond what their bodies would normally produce. They are restoring a deficit.

This clinical context reframes public conversations like the one Watts has been leading. When a woman in her mid-thirties loses ovarian function, the risk-benefit calculation for HRT is different from that of a 60-year-old considering initiation a decade after menopause. The 2017 Hormone Therapy Position Statement from The Menopause Society (formerly NAMS) emphasizes that age at initiation and time since menopause are the two most important variables shaping HRT's risk profile.

The HealthRX.com Medical Team Take

Watts's story illustrates a pattern the HealthRX.com Medical Team sees frequently in clinical discussions around menopause: women who experience early symptoms but receive delayed or dismissive care. Her public disclosure that she spent years without a clear diagnosis aligns with survey data showing that 73% of women do not treat their menopause symptoms and that many clinicians receive fewer than five hours of menopause education in medical school.

The HealthRX.com Medical Team notes three things that make Watts's public record clinically relevant:

Early onset demands early intervention. The bone density a woman loses between ages 36 and 51 without estrogen replacement is not recoverable through lifestyle alone. Data from the Women's Health Initiative confirmed that estrogen therapy reduces hip fracture risk by 33%. For a woman who would otherwise spend 15 extra years in an estrogen-deficient state, the cumulative skeletal benefit is significant.

The WHI legacy still distorts patient decisions. The 2002 WHI headlines linking HRT to breast cancer created a generation of estrogen avoidance. Subsequent reanalysis showed that the elevated breast cancer signal was confined to the estrogen-plus-synthetic-progestin arm and was not statistically significant until after five years of use. The estrogen-only arm actually showed a trend toward reduced breast cancer incidence. Watts has spoken publicly about the fear she encountered when she first explored HRT, a fear the HealthRX.com Medical Team attributes directly to the initial WHI misinterpretation reaching patients without adequate clinical context.

Celebrity brands can raise awareness but are not substitutes for prescriptions. Stripes Beauty sells topical products and supplements. These are not prescription HRT. The HealthRX.com Medical Team supports Watts's work in normalizing menopause conversations, but emphasizes that over-the-counter menopause products do not replicate the systemic estrogen exposure that treats vasomotor symptoms or protects bone. Women experiencing symptoms consistent with perimenopause should seek evaluation from a clinician trained in menopausal medicine, not rely on consumer products alone.

Side Effects and Risk Profile of HRT

Common side effects of systemic HRT include breast tenderness, bloating, headache, and irregular bleeding during the first months of therapy. These typically resolve within three to six months. Transdermal delivery avoids first-pass hepatic metabolism, which reduces the risk of venous thromboembolism (VTE) compared to oral formulations. A large UK cohort study found no significant increase in VTE risk with transdermal estrogen, even in women with elevated BMI.

The most discussed long-term risk is breast cancer. Current evidence from the Collaborative Group on Hormonal Factors in Breast Cancer indicates that combined estrogen-progestogen therapy is associated with a small absolute increase in breast cancer risk (approximately 1 additional case per 1,000 women per year of use beyond five years). Estrogen-only therapy carries a lower or neutral risk. The type of progestogen matters: micronized progesterone appears safer than medroxyprogesterone acetate in observational data, though no randomized trial has directly compared breast cancer outcomes between the two.

Contraindications to systemic HRT include active or recent breast cancer, undiagnosed vaginal bleeding, active liver disease, and a history of VTE (for oral formulations). Women with these conditions may still be candidates for low-dose vaginal estrogen, which acts locally and produces minimal systemic absorption.

Frequently asked questions

›